ADAPTIMMUNE LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website

Clinical Trials

CT Antigen TCR-Engineered T Cells for Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Treatment with NY-ESO-1c259-modified T cells

First Posted Date: 2013-07-04

Last Posted Date: 2019-01-10

Lead Sponsor: Adaptimmune

Target Recruit Count: 6

Registration Number: NCT01892293

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States

CT Antigen TCR-redirected T Cells for Ovarian Cancer.

Phase 1

Completed

Conditions: Ovarian Cancer

Interventions: Biological: NYESO-1c259 T cells

First Posted Date: 2012-03-30

Last Posted Date: 2019-06-27

Lead Sponsor: Adaptimmune

Target Recruit Count: 9

Registration Number: NCT01567891

Locations: 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
Stanford Cancer Institute, Stanford, California, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

and more 2 locations

Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma

Phase 1

Terminated

Conditions: Melanoma

Interventions: Genetic: Autologous genetically modified T cells, NY-ESO-1ᶜ²⁵⁹T

First Posted Date: 2011-05-09

Last Posted Date: 2019-01-10

Lead Sponsor: Adaptimmune

Target Recruit Count: 4

Registration Number: NCT01350401

Locations: 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States
🇺🇸
Washington University in St. Louis, Saint Louis, Missouri, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy